Sinovac Reports Unaudited First Quarter 2010 Financial Results

2010-05-14

Sinovac Reports Unaudited First Quarter 2010 Financial Results

- Conference call scheduled for Thursday, May 13, 2010 at 8:00 PM EDT –

Beijing – May 13, 2010 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.

First Quarter 2010 Financial Highlights (comparisons to First Quarter 2009)

l Sales for the first quarter decreased 32% to $4.4 million

l Operating loss for the first quarter was $865,000, compared to operating income of $646,000

l Net loss attributable to shareholders for the first quarter was $307,000, with loss per diluted share of $0.01

l Cash and cash equivalents at March 31, 2010 increased to $118.9 million, reflecting the closing of the common share public offering in February 2010

Business Highlights

· In April 2010, Sinovac’s joint venture, Sinovac Dalian, submitted an application to China’s State Food and Drug Administration (SFDA) to commence human clinical trials for its mumps vaccine. The proprietary mumps vaccine developed by Sinovac Dalian represents not only the first live attenuated vaccine for which Sinovac Dalian has filed a clinical trial application, but also the first candidate from the joint venture’s pipeline for which a clinical trial application has been submitted to and accepted by the SFDA since the formation of the joint venture in January 2010.

· In May 2010, Sinovac Biotech, through its wholly owned subsidiary Sinovac Biotech (Hong Kong) Ltd, made an initial cash contribution of 60 million RMB, or approximately $8.8 million, to Sinovac Dalian, the Company’s 30%-owned joint venture that was established in January 2010.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, “As we indicated in early April, the demand for the vaccinations in the private pay market across China was unfortunately impacted by the product safety media reports that the SFDA subsequently determined to be unfounded. As a leading supplier of hepatitis A and seasonal influenza vaccines to the private pay and public markets, our first quarter 2010 sales were impacted by the reduced industry demand. Our domestic sales and marketing strategy is being augmented to reflect the current landscape. We are expanding our geographic reach by focusing on the rural markets and are providing physician education programs to drive growth in the private pay market. We continue to collaborate with our local distribution partners to obtain requisite approvals in targeted international markets, including India, Mexico and the Philippines.”

Mr. Yin continued, “Given our long term expectations for increasing demand for our vaccines products, initiatives are underway to bring on additional capacity that will enable us to both expand production of our commercialized vaccines and commence production of our pipeline vaccines in a condensed timeframe upon receipt of production licenses. At our 300,000 square foot production facility in the Changping District, Beijing, we are targeting completion of the build-out of two new production lines in the second half of 2010. These new production lines will have a combined annual capacity of approximately 40 million doses and will be utilized to manufacture our currently marketed flu vaccines and our pipeline EV71 vaccine. At Sinovac Dalian’s 200,000 square foot production facility, two vaccine production lines are operational – one for animal cell cultured vaccines and one for live attenuated vaccines.”

Mr. Yin concluded, “Advancing our research and development pipeline of proprietary vaccines continues to be a critical component of our growth strategy. Through our Sinovac Dalian joint venture, we have already submitted a clinical trial application for the mumps vaccine to the SFDA, exemplifying our commitment to building our pipeline and expanding our portfolio of commercialized vaccines. During the quarter, we further strengthened our R&D team, adding specialists both at our headquarters and at our joint venture Through our in-house development and in collaboration with domestic and international partners, we are advancing our robust pre-clinical development pipeline that encompasses pneumococcal conjugated vaccine, rabies vaccine, HIB vaccine, meningitis vaccine, chickenpox (varicella) vaccine, and rubella vaccine.”

Financial Review for Three Months Ended March 31, 2010

First quarter 2010 results included the consolidation of the financial results from the 30%-owned joint venture, Sinovac Dalian, following its formation in January 2010.

Sales for the first quarter of 2010 were $4.4 million, down 32% from $6.6 million for the first quarter of 2009. The lower sales in the first quarter 2010 were attributable to the lower demand in the private pay market based on concerns over product safety given the recent media reports linking the improper storage of vaccines by a distributor to a few cases of serious adverse events in China’s Shanxi province. The media reports, which were not related to Sinovac and its products, impacted the entire vaccine industry in China and were subsequently proven to be unfounded based on the government’s investigation.

Sinovac’s sales breakdown by product was as follows.

	Three months ended March 31
	2010	2009
Sales
Healive	$ 2,539,634	$ 4,902,315
Bilive	541,059	1,196,177
Anflu	31,796	467,607
Panflu.1 (H1N1)	1,331,410	-
Total	$ 4,443,899	$ 6,566,099

Sales of the Panflu.1 (H1N1) vaccine represented 29.96% of total sales for the three months ended March 31, 2010. The H1N1 vaccine was sold to the Chinese government in accordance with the government purchase program.

Gross profit for the first quarter of 2010 was $3.6 million, with a gross margin of 80%, compared to $5.1 million and a gross margin of 78% for the same period of 2009. The gross margin for the first quarter of 2010 increased due to the product mix during the current year quarter.

Selling, general and administrative expenses for the first quarter of 2010 were $3.1 million, compared to $3.5 million in the same period of 2009. SG&A expenses as a percentage of first quarter 2010 sales were 70%, compared to 54% during the first quarter of the prior year. The higher SG&A expenses as a percentage of revenue resulted from the additional G&A expenses associated with the 30%-owned joint venture, partly offsetting the lower selling costs associated with the first quarter 2010 revenues.

Net research and development expenses for the first quarter 2010 were $908,000, compared to $759,000 in the same period of 2009. The increased R&D expenses in the first quarter of 2010 were primarily related to the continued development of EV71 vaccine, pneumococcal conjugated vaccine, rabies vaccines for human and animals, along with the mumps vaccine, which is currently under development at Sinovac Dalian.

Depreciation of property, plant and equipment and amortization of license and permits for the first quarter of 2010 rose to $425,000, compared to $165,000 for the same period of last year. The increase was primarily attributable to depreciation expense at Sinovac Dalian that was included in the first quarter 2010 consolidated results.

Total operating expenses for the first quarter of 2010 were $4.4 million, compared to $4.5 million in the comparative period in 2009.

The operating loss for the three months ended March 31, 2010 was $865,000, compared to operating income of $646,000 for the same period of the prior year. The operating loss in the first quarter of 2010 was attributable to the increased administrative expenses from Sinovac Dalian, reduced sales and higher R&D expenses.

Net income for the first quarter of 2010 included $124,000 of interest and financing expenses, $493,000 of interest and other expenses and $269,000 of income tax recovery. Net income for the same period of 2009 included $126,000 of interest and financing expenses, $93,000 of interest and other income, and $482,000 of income tax expenses. Net loss attributable to shareholders for first quarter of 2010 was $307,000, or $0.01 loss per diluted share, as compared to net income attributable to shareholders of $25,000, or $0.00 per diluted share, in the same period of 2009.

As of March 31, 2010, Sinovac’s cash and cash equivalents totaled $118.9 million, compared to $75.0 million as of December 31, 2009. The increase in cash and cash equivalents primarily reflects the contribution of approximately $62.0 million in net proceeds from the public offering of common shares, which closed in February 2010.

Recent Developments

Sinovac’s 30%-owned joint venture, Sinovac Dalian, submitted an application to the SFDA to commence human clinical trials for its mumps vaccine. The proprietary mumps vaccine developed by Sinovac Dalian represents not only the first live attenuated vaccine for which Sinovac has filed a clinical trial application, but also the first candidate from the joint venture’s pipeline for which a clinical trial application has been submitted to and accepted by the SFDA since the formation of the joint venture in January 2010.

After receiving regulatory approval from China’s State Administration of Foreign Exchange, Sinovac Biotech, through its wholly owned subsidiary Sinovac Biotech (Hong Kong) Ltd, made an initial cash contribution of 60 million RMB, or approximately $8.8 million, to Sinovac Dalian. Dalian Jin Gang Group, the other party, made an asset contribution, inclusive of its manufacturing facilities, production lines and land use rights, with an appraised value of 140 million RMB, or approximately $20.5 million. Equity interest is currently divided 30% and 70% between Sinovac and Dalian Jin Gang Group, respectively. Pursuant to the agreement executed between Sinovac and Dalian Jin Gang Group, Sinovac intends to increase its equity shares to 55%, in exchange for a cash contribution of 50 million RMB, or approximately $7.3 million, on or before December 31, 2010.

2010 Guidance

Sinovac anticipates that the impact of the unfounded Shanxi media reports on the vaccine industry will gradually diminish as the SFDA has clarified that the fatalities were not connected to the vaccines; however it may take some time for public perceptions of vaccine safety to recover. As such, the Company has adjusted its total 2010 sales expectations to the range of approximately $60.0 million to $67.0 million. It is anticipated that the 2.15 million doses of Panflu.1 purchased by the government will be delivered to the local CDC and the remaining 8.74 million doses of Panflu.1 will be stockpiled by the government in the Company’s warehouse facility in 2010. The revenue from the 2.15 million H1N1 vaccine doses, which are expected to be delivered this year, is included in the 2010 sales guidance. The Company expects that the revenue from the 8.74 million H1N1 vaccine doses will be recognized in 2011, if they have not been delivered before the shelf life of the vaccine expires.

In 2010, the Company expects to advance the clinical development of its pipeline products as follows: (i) to commence clinical trials in China for its enterovirus 71 (EV 71) vaccine and Japanese encephalitis vaccine upon receiving approval of its clinical trial applications from SFDA; (ii) to file the clinical trial application with the SFDA for its pneumococcal conjugate vaccine; and (iii) to commence clinical trials in China for the mumps vaccine under development at Sinovac Dalian upon receiving approval for its clinical trial application from the SFDA The Company intends to continue executing its business plan at the Sinovac Dalian and the Changping facilities to increase production capacity of its commercialized vaccines and prepare for the commercialization of its pipeline products.

Conference Call Details

The Company will host a conference call on Thursday, May 13, 2010 at 8:00 p.m. EDT (8:00 a.m. on May 14, 2010 China Standard Time) to review the Company's financial results for the first quarter ended March 31, 2010 and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00 p.m. EDT on May 13, 2010 until May 27, 2010. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 350462. A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com. A webcast replay can be accessed on the corporate website beginning May 13, 2010 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), Anflu® (seasonal influenza), Panflu™ (pandemic influenza (H5N1)), and Panflu.1™ (pandemic influenza A (H1N1)). Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, pneumococcal infection, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x9871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors:

Amy Glynn/Stephanie Carrington

The Ruth Group

Tel: +1-646-536-7023/7017

Email: aglynn@theruthgroup.com

scarrington@theruthgroup.com

Media

Janine McCargo

The Ruth Group

Tel: +1-646-536-7033

Email: jmccargo@theruthgroup.com

SINOVAC BIOTECH LTD.

Incorporated in Antigua and Barbuda

Consolidated Balance Sheets

(Unaudited)

(Expressed in U.S. Dollars)

March 31,

December 31,

2010

2009

ASSETS

Current assets

Cash and cash equivalents

118,932,465

74,953,212

Restricted cash

6,440

64,400

Short-term investments

8,338,088

7,313,149

Accounts receivable – net

22,713,648

24,540,134

Inventories

13,779,138

9,599,118

Prepaid expenses and deposits

802,158

466,346

Due from related party

3,286,046

Deferred tax assets

1,133,010

1,375,174

Total current assets

168,990,993

118,311,533

Property, plant and equipment

40,624,385

22,306,688

Deposits for acquisition of assets

8,264,946

Long-term inventories

2,642,242

2,642,734

Deferred tax assets

507,363

520,077

Licenses and permits

595,660

695,109

Due from related party

3,286,046

224,911,635

144,476,141

Total assets

LIABILITIES AND EQUITY

Current liabilities

Loans payable

17,700,151

17,697,821

Accounts payable and accrued liabilities

11,163,976

17,784,509

Income tax payable

3,786,171

6,413,734

Deferred revenue

5,153,407

5,386,749

Deferred research grants

1,360,908

1,331,476

Deferred tax liability

1,835,953

1,398,123

Total current liabilities

41,000,566

50,012,412

Deferred government grants

2,581,188

2,646,669

Loans payable

8,264,946

Long term payable

407,847

407,794

Deferred revenue

6,943,738

6,942,824

Total long term liabilities

18,197,719

9,997,287

Total liabilities

59,198,285

60,009,699

Commitments and contingencies

EQUITY

Preferred stock

Authorized 50,000,000 shares at par value of $0.001 each

Issued and outstanding: nil

Common stock

54,097

42,585

Authorized: 100,000,000 shares at par value of $0.001 each

Issued and outstanding: 54,097,261 (2009– 42,585,261 )

Additional paid in capital

104,493,734

42,533,876

Accumulated other comprehensive income

4,232,442

4,225,196

Dedicated reserves

9,863,251

Retained earnings

13,685,977

13,993,287

Total stockholders' equity

132,329,501

70,658,195

Non-controlling interests

33,383,849

13,808,247

Total equity

165,713,350

84,466,442

Total liabilities and equity

224,911,635

144,476,141

SINOVAC BIOTECH LTD.

Incorporated in Antigua and Barbuda

Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)

Three Months Ended March 31, 2010 and 2009

(Unaudited)

(Expressed in U.S. Dollars)

Three months ended

March 31

2010

2009

Sales

4,443,899

6,566,099

Cost of sales - (exclusive of depreciation of land-use rights and amortization of licenses and permits of $104,793 (2009-$104,633 )

883,475

1,447,770

Gross profit

3,560,424

5,118,329

Selling, general and administrative expenses

3,092,248

3,547,623

Research and development expenses - net of

907,959

759,441

$17,554 (2009 - $58,311) in government research grants

Depreciation of property, plant and equipment and amortization of licenses and permits

425,427

164,869

Total operating expenses

4,425,634

4,471,933

Operating income (loss)

-865,210

646,396

Interest and financing expenses

-124,375

-126,200

Interest income and other income (expenses)

-492,592

93,131

Income (loss) before income taxes and non-controlling interests

-1,482,177

613,327

Income tax recovery (expenses)

269,479

-481,768

Consolidated net income (loss) for the period

-1,212,698

131,559

Loss (income) attributable to non-controlling interests

905,388

-106,880

Net income (loss) attributable to stockholders

-307,310

24,679

-1,212,698

131,559

Net income (loss)

Other comprehensive income

Foreign currency translation adjustment

8,723

64,899

Total comprehensive income (loss)

-1,203,975

196,458

Comprehensive loss (income) attributable to non-controlling interests

903,911

-123,043

Comprehensive income (loss) attributable to stockholders

-300,064

73,415

Earnings (loss) per share – basic and diluted

-0.01

Weighted average number of shares of common stock outstanding

– Basic and Diluted

49,873,422

42,890,695

SINOVAC BIOTECH LTD.
Incorporated in Antigua and Barbuda
Consolidated Statements of Cash Flows
Three Months Ended March 31, 2010 and 2009
(Unaudited)
(Expressed in U.S. Dollars)
		Three months ended
		March 31
		2010		2009

Cash flows used in operating activities
Net income (loss) for the period	$	(1,212,698)	$	131,559
Adjustments to reconcile net income to net cash
used in operating activities:
- deferred income taxes		692,520		157,394
- stock-based compensation		103,664		66,503
- inventory provision		16,206		-
- provision for doubtful accounts		-		868,938
- write-off equipment and loss on disposal		687,095		(9,783)
- research and development expenditures qualified for government grant		(17,554)		(58,311)
- depreciation of property, plant and equipment and amortization of licenses and permits		891,007		483,670
- deferred government grant recognized in income		(65,830)		(51,316)
- accounts receivable		1,829,731		(2,462,999)
- inventories		(3,771,749)		(2,331,763)
- income tax payable		(2,628,408)		(885,252)
- prepaid expenses and deposits		(335,770)		30,904
- long term payable, deferred revenue and advances from customers		(234,054)		-
- accounts payable and accrued liabilities		(6,100,581)		(2,771,775)

Net cash used in operating activities		(10,146,421)		(6,832,231)

Cash flows from (used in) financing activities
- Loan proceeds		8,265,031		-
- Proceeds from issuance of common stock net of share issuance costs		61,867,706		-
- Repurchase of common shares		-		(319,643)
- Loan to non-controlling shareholder of Sinovac Beijing		(6,572,159)		(1,460,600)
- Government grant received		46,811		-

Net cash provided by (used in) financing activities		63,607,389		(1,780,243)

Cash flows used in investing activities
- Restricted cash		57,961		-
- Proceeds from disposal of equipment		189,876		-
- Proceeds from redemption of short-term investments		7,314,187		-
- Purchase of short-term investments		(8,338,173)		-
- Prepaid for acquisition of new facility		(8,265,031)		-
- Acquisition of property, plant and equipment		(448,165)		(1,011,492)

Net cash used in investing activities		(9,489,345)		(1,011,492)

Exchange gain on cash and cash equivalents		7,630		38,743

Increase in cash and cash equivalents		43,979,253		(9,585,223)

Cash and cash equivalents, beginning of period		74,953,212		32,894,102


Cash and cash equivalents, end of period	$	118,932,465	$	23,308,879

Supplemental disclosure of cash flow information:
Cash paid for interest	$	268,279	$	123,402
Cash paid for income taxes	$	1,653,353	$	1,209,626

Supplemental schedule of non-cash activities:
Supplemental schedule of non-cash activities:
Acquisition of property, plant and equipment included in
Accounts payable and accrued liabilities	$	798,541	$	1,092,789

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.